touchPODCAST

Getting personal: Individualizing therapy for cold agglutinin disease

touchEXPERT OPINIONS for touchONCOLOGY

Listen to two leading experts give their insights on the recommended workup for a timely and accurate diagnosis, as well as the evolving treatment landscape, and importance of individualizing therapy for patients with cold agglutinin disease. 

 

The experts

• Dr Catherine M Broome, MedStar Georgetown University Hospital Washington DC, USA
• Dr Ilene Ceil Weitz, Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine Los Angeles, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Alexion AstraZeneca Rare Disease and is jointly provided by USF Health and touchIME.

 

For further information visit our website: https://touchoncologyime.org/getting-personal-individualizing-therapy-for-cold-agglutinin-disease/

Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?

touchPANEL DISCUSSION for touchIMMUNOLOGY

Listen to a panel of leading experts discuss the pathophysiology of cold agglutinin disease (CAD), the steps needed for an accurate diagnosis, and how emerging treatment options are changing the management of patients with primary CAD. 

The experts

• Prof. Morie Gertz, Mayo Clinic, Rochester, Minnesota, USA
• Prof. Bernd Jilma, Medical University of Vienna, Austria
• Dr Shirley D'Sa, University College London Hospitals, UK

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Sanofi and is jointly provided by USF Health and touchIME. 

For further information visit: touchIMMUNOLOGY

Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?

touchPANEL DISCUSSION for touchONCOLOGY

Listen to a panel of leading experts discuss the pathophysiology of cold agglutinin disease (CAD), the steps needed for an accurate diagnosis, and how emerging treatment options are changing the management of patients with primary CAD. 

The experts

• Prof. Morie Gertz, Mayo Clinic, Rochester, Minnesota, USA, 
• Prof. Bernd Jilma, Medical University of Vienna, Austria, 
• Dr Shirley D'Sa, University College London Hospitals, UK

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Sanofi and is jointly provided by USF Health and touchIME. 

For further information visit: https://touchoncologyime.org/understanding-the-immunopathogenesis-of-cad-what-are-the-implications-of-new-and-emerging-therapies

Advances in immunotherapies and targeted treatments for patients with bladder cancer: An update from ESMO 2022

touchCONGRESS for touchONCOLOGY

Listen to urological cancer expert Prof. Axel Merseburger (Germany) review key data presented at ESMO 2022 exploring recent advances in immunotherapies and targeted treatments for patients with bladder cancer.  He then offers his views on the potential impact of these data on clinical practice, alongside expert insights from Dr Bradley McGregor (USA) and Prof. Andrea Necchi (Italy). 

 

OVERVIEW

Data Review with Prof. Merseburger (00:00)

Expert interviews with Prof. Merseburger, Dr McGregor and Prof. Necchi answering the questions below

INTERVIEW QUESTIONS

1. Based on data recently presented at ESMO 2022, how do you think new and emerging immunotherapy agents and targeted treatments for patients with bladder cancer will impact the treatment landscape? (31:45)
2. How can key learnings from ESMO 2022 be integrated into clinical practice when choosing between available regimens? (37:42)
3. How is our understanding of the role of PD-L1 as a biomarker in bladder cancer evolving in light of recent data, and what are the possible implications for clinical practice? (44:35)
4. What unmet needs remain surrounding biomarkers beyond PD-L1 in bladder cancer, and what are the prospects for biomarker-driven individualized treatment decisions in future? (51:14)

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical educational grant from Seagen Inc. and Astellas Pharma Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:

https://touchoncologyime.org/bladder-cancer-esmo2022-touchcongress/https://touchoncologyime.org/bladder-cancer-esmo2022-touchcongress/

 

Considering the needs and preferences of patients at each treatment decision-making moment

touchMDT for touchNEUROLOGY

Listen to a patient advocate and person living with MS and two MS specialist neurologists discuss the importance of understanding the needs and preferences of patients at each treatment decision-making moment.

The multidisciplinary team

• Patient advocate/person living with MS: Ms Nele Handwerker, Germany
• Neurologist/MS specialist: Prof. Tjalf Ziemssen, Germany
• Neurologist/MS specialist: Prof. Tobias Derfuss, Switzerland

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:

www.touchNEUROLOGY.com

Imaging disease progression in MS

touchMDT for touchNEUROLOGY

Listen to an imaging specialist and two neurologists specializing in MS care discuss the imaging modalities available to assess disease progression in MS.

The multidisciplinary team

• Imaging specialist: Dr Francesca Bagnato, USA
• Neurologist/MS specialist: Prof. Tjalf Ziemssen, Germany
• Neurologist/MS specialist: Prof. Tobias Derfuss, Switzerland

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:

https://touchneurology.com/cme/integrating-practice-to-enhance-ms-patient-care/

Managing MS in patients over their lifetime

touchMDT for touchNEUROLOGY

Listen to two neurologists specializing in MS care discuss the management of MS throughout the lifetime of patients and consider treatment switching strategies at key milestones (e.g. during the paediatric, childbearing and elderly years).

The experts

• Neurologist/MS specialist: Prof. Tjalf Ziemssen, Germany
• Neurologist/MS specialist: Prof. Tobias Derfuss, Switzerland

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 

https://touchneurology.com/cme/integrating-practice-to-enhance-ms-patient-care/ 

Navigating the evolving treatment landscape in mTNBC: What are the key considerations for clinical practice today?

touchIN CONVERSATION for touchONCOLOGY

 

Listen to two breast cancer experts, Prof. Peter Schmid and Dr Marleen Kok discuss the mechanisms of action and latest data for  emerging treatment options and how they are changing the management of metastatic triple negative breast cancer (mTNBC). The discussion is guided by pre-canvassed questions from the breast cancer clinical community.

This touchPODCAST is for HCPs only. 

This activity is funded by an unrestricted independent medical education grant from Gilead and is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/evolving-treatment-landscape-in-mtnbc/

Managing disease progression: Considerations for treatment selection and sequencing

touchMDT for touchRESPIRATORY

Listen to leading specialists from the MDT discuss the role of monitoring in identifying disease progression, and review the current and emerging treatment options for a patient with a pancreatic NET.

The multidisciplinary team and patient

• Medical oncologist: Dr Diane Reidy-Lagunes, USA
• Nuclear medicine physician: Dr Thomas Hope, USA
• Endocrinologist: Prof. Dr med. Marianne Pavel, Germany
• Nurse specialist: Catherine Bouvier Ellis, UK

This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent medical educational grant from Advanced Accelerator Applications.  This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchrespiratoryime.org/mdt-management-nets/ 

 

Supporting treatment adherence: What strategies are needed for safety management?

touchMDT for touchRESPIRATORY

Listen to leading specialists from the MDT discuss the side effects associated with treatment in a patient with liver-dominant disease and the importance of addressing patient needs in ensuring adherence to treatment.  

The multidisciplinary team and patient

• Medical oncologist: Dr Diane Reidy-Lagunes, USA
• Nuclear medicine physician: Dr Thomas Hope, USA
• Nurse specialist: Catherine Bouvier Ellis, UK

This touchPODCAST is for HCPs only.

Funding for this touchPODCAST is from an unrestricted independent medical educational grant from Advanced Accelerator Applications.  This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchrespiratoryime.org/mdt-management-nets/